Plasma Expressor Machine Market Outlook:
Plasma Expressor Machine Market size was valued at approximately USD 127 million in 2024 and is projected to reach USD 311 million by the end of 2037, rising at a CAGR of 7.5% during the forecast period, i.e., 2025–2037. In 2025, the industry size of the plasma expressor machine is evaluated at USD 136 million.
Recent years have seen a steady increase in plasma-derived medicinal products (PDMP) needs fueled by increased diagnoses for indications seeking immunoglobulin therapies and volume expanders. As the CDC reports, nearly 7 million people in the U.S. receive a plasma-derived therapy every year. The global lack of domestic plasma collections means that governments on international, national, and local levels must import plasma or PDMP. This also creates pressure on uptake of equipment. There are strict rules around import/export of PDMP products by the FDA’s CBER, that may not happen without considerable, safety surrounding screening and testing. This results in demand for plasma expressor machines in both developing and developed countries. Shortages are often reported. The business model for expressor system manufacturers must support domestic API production and import with compliance. The globally restricted supply system likely creates a certainty in demand for capital and capital equipment manufactured for fit within the plasma collection or processing lifecycle.
Plasma Expressor Machine Market Growth Drivers and Challenges
Growth Drivers
- Growing demand for plasma products: It is crucial to permanently establish the interdependence relationship between manufacturing and plasma procurement. Plasma-derived medicines (PDMPs) provide lifesaving treatments to thousands of patients. The increasing global demand for PDMPs, including immunoglobulins and clotting factors, is a direct result of the increased prevalence of diseases that are treated with PDMPs. The immunoglobulin market alone continues to grow as the prevalence of primary immunodeficiency diseases rises, LINK, and plasma separation technologies must efficiently process these rising volumes of donated plasma. For instance, in 2021, 68% of the World's plasma was supplied by a US plasma donor in the United States, which emphasizes the growing global demand for plasma-derived products and not just supply (CNBC). Moreover, the emerging emphasis on providing personalized medicine and plasma-based therapies will only increase the demand for PDMPs.
- Increasing incidence of blood disorders: The rise of diseases that require plasma-based therapies, including hemophilia, leukemia, lymphoma, and autoimmune disorders, spurs the need for the optimal separation of plasma. For instance, according to the CDC, in the United States, it is estimated that between 20,000 and 34,000 males are affected by hemophilia who require treatment using plasma-derived clotting factors. These diseases require regular infusions of plasma-derived products. Improved identification of these disorders based on aging population demographics and new diagnostics will only increase the patient count, and thus the need for plasma separation.
Plasma Expressor Machine Market Positioning Through Innovation
In recent years, plasma expressor machine manufacturers have made a concerted push for regulatory compliance, automation, and strategic partnerships to generate revenue. For instance, using the FDA CBER-cleared NexSys PCS with Persona Technology, Haemonetics generated an 8–13% increase in plasma yield per donation. By focusing on automating processes, biosafety protocols, and regulatory readiness, these companies will create a longer-term procurement opportunity in public health and private-sector settings around the world.
Annual Revenue Growth in 2023
|
Manufacturer |
Innovation Focus |
Annual Revenue Growth (USDM) |
|---|---|---|
|
Haemonetics |
Persona tech – FDA-cleared (auto yield) |
+17 |
|
Terumo BCT |
GMP-compliant apheresis disposables |
+11 |
|
Grifols |
WHO-prequalified dual-channel systems |
+15 |
|
Fresenius Kabi |
Public-sector collection system (Scotland tender) |
+0.6* |
Revenue Feasibility Models for Plasma Expressor Machines
The plasma expressor machine makers have put together partnership options with contractual models to broaden their reach within the plasma expressor machine market. In India, the suppliers worked with local healthcare resources to partner with public plasma centers from 2022 to 2024. The partnership approach had a benefit of 13% revenue enhancements from improved exposure to the machines. In the U.S., the makers partnered with public military hospitals after using the U.S. Department of Defense's funding. With demand for processing plasma, due to increased procedure returns from the industry, to continue to raise awareness at the global level, these types should provide a path for large-scale industry players to expand towards revenue increase by untapping devices through 2030.
Challenges
- Lack of domestic plasma supply: According to World Health Organizations (WHO) 2022 report, between 2008-2018, only 57 of 170 countries were processing plasma at home and more than 90 countries were exclusively dependent on imported plasma. Absence of an adequate domestic supply of plasma means there is less economic, operational, and strategic pressure to procure or retain plasma expressor machines, resulting in underutilized equipment and hence shrinking the incentive for investment or for the development of the facilities and infrastructure required to build capacity to collect and process plasma.
- Capital investment constraints & public payer coverage gaps: Plasma expressor machines require extensive infrastructure, including refrigerators, safety monitoring, and educated staff. The WHO stated that in low- and middle-income countries, budget constraints greatly reduce the ability of health facilities to purchase capital equipment. Purchasing plasma expressor machines is limited by a lack of a direct funding mechanism through the public system for either the equipment or the machinery consulting devices.
Plasma Expressor Machine Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7.5% |
|
Base Year Market Size (2024) |
USD 127 million |
|
Forecast Year Market Size (2037) |
USD 311 million |
|
Regional Scope |
|
Plasma Expressor Machine Market Segmentation:
End User Segment Analysis
The public blood services segment of the plasma expressor machine market is projected to hold a dominant 33% revenue share by the end of 2037. Around the world, public blood services account for more than half of all plasma donations. The World Health Organization (WHO) statistics indicate that publicly-funded blood services account for approximately 53% of worldwide plasma collections. Governments provide funding to blood services through national blood policies, which seek to ensure a consistent supply of plasma and have access to equipment that meets the WHO standards for safety and traceability. The demand from government policies creates a large, sustainable public sector revenue stream for donors, cementing public services as the largest segment of users, by revenue.
Application Segment Analysis
The hospital apheresis centers segment is poised to account for 28% revenue share in the plasma expressor machine market. In high-income countries, hospital-based apheresis units are crucial components of therapeutic plasma exchange and other life-saving procedures. CDC recommendations indicate that hospitals use sterile, closed-system expressor to minimize contamination risk. FDA-cleared devices with stable documentation supporting safety and efficiencies have a competitive advantage in the tendering processes. With hospitals working on thin margins for unit costs, we can expect that technologies that provide shorter downtimes and a higher rate of work throughput will impact acquisition decisions the most significantly. That will continually reinforce leading revenue share for this sub-segment through 2037.
Our in-depth analysis of the global plasma expressor machine market includes the following segments:
|
Segment |
Subsegments |
|
Application |
|
|
End User |
|
|
Delivery Model |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Plasma Expressor Machine Market Regional Analysis
North America Market Insights
The North America plasma expressor machine market is projected to account for a leading share of 31% by the end of 2037. The growth can be attributed to the strong federal investment, growing public-sector contracts, and strong healthcare infrastructure. Federal agencies—including the CDC's Office of Blood Safety—conservatively estimate the U.S. requires over 6,400 plasma units a day. The NIH and HHS committed to allocating approximately 7% of blood safety budgets to modernize collection infrastructure, encourage the acquisition of new machines, and assist with both regulatory and resource requirements.
Canada’s plasma expressor machine market similarly increased domestic capacity by investing USD 15 million from 2021 - 2024 to build new plasma collection centers furnished by Canada Blood Services. The way that Medicaid and Medicare indirectly reimburse through purchasing equipment provides a strong fiscal incentive for hospitals to acquire machines whenever compliance meets CDC and FDA standards. Current trends surrounding the percentage of public–private partnerships with the government, synchrony of regulatory permissions such as the FDA's regulations and the CDC guidance, and donor-driven mechanisms of cost containment ensure revenue secured and partnership attractiveness with machine providers through 2037.
The U.S. plasma expressor machine market is set for rapid growth, supported by federal healthcare funding, Medicaid and Medicare reimbursement changes, and national plans to improve plasma infrastructure. In 2023, the CDC allocated USD 4 billion, or 8% of its healthcare budget, towards plasma-related technology. The U.S. Department of Defense (DoD) also added to the demand for blood management modernization programs to support battlefield transfusion and trauma response. Plasma expressor machine market momentum is bolstered by support from the American Medical Association (AMA) and the Biotechnology Innovation Organization (BIO) to improve the FDA device approval process.
Asia Pacific Market Insights
Asia Pacific will account for approximately 29% of the global plasma expressor machine market share by 2037. This growth is being exponentially driven by the recent emphasis on public health security and self-sufficiency by governments in the region. Japan's MHLW and AMED are applying plasma automation into the plans for pandemic preparedness based on lessons learned from COVID-19. China's NMPA improved regulatory pathways for importing plasma devices and expedited the approval process for devices when deployed under emergency protocols starting in 2020. Malaysia introduced digital systems for blood banking (BBISv2) at each of its 22 sites to provide traceability and support the deployment. Combining regulatory support, infrastructure capital investment, and national policies provides a primordial position for the emergence of expressor machine distribution and adoption growth in the region through to 2037.
China's plasma expressor machine market represents a 20% increase from the previous year, with the main driver being hospital procurement. Plasma collection ebbed following the pandemic in 2020, but reported a steep rebound to new norm levels. The NMPA had various fast-track methods and Article 76 emergency registration approvals available, which allowed for approximate reductions of months in the device approval period. For the future, the various avenues of strong procurement expansion, increased plasma collection, and regulatory acceleration culminate to support China’s leading CAGR, and further plasma expressor machine market expansion projection through 2037.
2037 Plasma Expressor Machine Industry Revenue Share (APAC)
|
Country |
2037 Market Revenue Share (%) |
Market Highlights |
|
China |
22.2% |
Over 2.1 million patients treated in 2023; 15% increase in 5-year gov. spending |
|
Japan |
12.2% |
¥120B allocated in 2024; MHLW + AMED funds expanding device usage in hospitals |
|
India |
6.2% |
$1.22B government spending in 2023; plasma therapy doubled since 2015 |
|
South Korea |
5.2% |
300,000+ plasma procedures reimbursed annually; $450M in device R&D in 2023 |
|
Malaysia |
5.5% (shared with other nations) |
Treatments doubled 2013–2023; government funding up 20% over 10 years |
Key Plasma Expressor Machine Market Players:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The new plasma expressor machines are characterized by strategic innovation and regional diversity. Generally, larger known companies, such as Haemonetics and Grifols, dominated with new integrated plasma management systems. The notable plasma expressor machines, such as Terumo and Fresenius Kabi, were focused on highly automated efficiencies. Other firms from emerging economies, such as Medion Healthcare (India) and SNJ Medical (Malaysia), focused on the customer priorities of regional affordability with specific customization. These firms have used national health agency partnerships, regional localization, and eventually increased research and development on the miniaturization of devices and automation to increase their scope of operations in highly regulated with price price-sensitive markets. Developments in new medical devices, along with programs and regulations are being modified continuously across a variety of device classes and user contexts.
|
Company Name |
Country |
Market Share (2037) |
|---|---|---|
|
Terumo Corporation |
Japan |
11.4% |
|
Haemonetics Corporation |
USA |
13.2% |
|
Fresenius Kabi |
Germany |
9.4% |
|
Grifols S.A. |
Spain |
10.2% |
|
Macopharma |
France |
6.1% |
|
Baxter International Inc. |
USA |
xx% |
|
Kawasumi Laboratories |
Japan |
xx% |
|
JMS Co. Ltd. |
Japan |
xx% |
|
Biosafe SA (GE Healthcare) |
Switzerland |
xx% |
|
Medion Healthcare Pvt. Ltd. |
India |
xx% |
|
Nikkiso Co., Ltd. |
Japan |
xx% |
|
SNJ Medical Technology |
Malaysia |
xx% |
|
Delcon Srl |
Italy |
xx% |
|
Fenwal Inc. (Fresenius Kabi) |
USA |
xx% |
|
Compoline Systems Pty Ltd |
Australia |
xx% |
Below are the areas covered for each company in the plasma expressor machine market:
Recent Developments
- In January 2025, Terumo launched its SmartFlow-Auto Expressor designed specifically for high-volume plasma locations. The product features automatic clamp release and cloud performance analytics. In Japan and China, the equipment helped increase center throughput by approximately 17%.
- In March 2024, Haemonetics launched its updated NextGen Plasma Expressor PX4000. The plasma expressor uses Artificial Intelligence-based pressure sensors to extract plasma at optimal rates.
- Report ID: 3991
- Published Date: Jun 19, 2025
- Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Plasma Expressor Machine Market Report Scope
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
